Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
127.57
+0.40 (0.31%)
Nov 13, 2026, 4:00 PM EST - Market closed
Kymera Therapeutics Employees
Kymera Therapeutics had 285 employees as of September 30, 2026. The number of employees increased by 60 or 26.67% compared to the same quarter last year. That makes Kymera Therapeutics the 24,268th largest employer in the world and 3,114th in the United States.
Employees
285
Change (1Y)
60
Growth (1Y)
26.67%
Revenue / Employee
$358,719
Profits / Employee
-$1,226,053
Market Cap
10.89B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 285 | 60 | 26.67% |
| Jun 30, 2026 | 273 | 55 | 25.23% |
| Mar 31, 2026 | 253 | 45 | 21.63% |
| Dec 31, 2025 | 238 | 50 | 26.60% |
| Sep 30, 2025 | 225 | 41 | 22.28% |
| Jun 30, 2025 | 218 | 37 | 20.44% |
| Mar 31, 2025 | 208 | 22 | 11.83% |
| Dec 31, 2024 | 188 | 1 | 0.53% |
| Sep 30, 2024 | 184 | -8 | -4.17% |
| Jun 30, 2024 | 181 | 0 | - |
| Mar 31, 2024 | 186 | 12 | 6.90% |
| Dec 31, 2023 | 187 | 20 | 11.98% |
| Sep 30, 2023 | 192 | 23 | 13.61% |
| Jun 30, 2023 | 181 | 21 | 13.13% |
| Mar 31, 2023 | 174 | 31 | 21.68% |
| Dec 31, 2022 | 167 | 26 | 18.44% |
| Sep 30, 2022 | 169 | 33 | 24.26% |
| Jun 30, 2022 | 160 | 48 | 42.86% |
| Mar 31, 2022 | 143 | 51 | 55.43% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Madrigal Pharmaceuticals | 915 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| TG Therapeutics | 399 |
| Krystal Biotech | 295 |
| Summit Therapeutics | 265 |
KYMR News
- 12 days ago - Kymera Therapeutics price target raised to $170 from $139 at Barclays - TheFly
- 14 days ago - Kymera Therapeutics price target raised to $150 from $146 at Morgan Stanley - TheFly
- 15 days ago - Kymera Therapeutics price target raised to $144 from $140 at Raymond James - TheFly
- 15 days ago - Kymera Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 15 days ago - Kymera Therapeutics Earnings release: Q3 2026 - Filings
- 15 days ago - Kymera Therapeutics Quarterly report: Q3 2026 - Filings
- 15 days ago - Kymera Therapeutics Slides: Q3 2026 - Filings
- 15 days ago - Kymera Therapeutics Slides: Company presentation - Filings